Skip to main content
SpringerLink
Log in

Modelling the Cost Effectiveness of Cholinesterase Inhibitors in the Management of Mild to Moderately Severe Alzheimer’s Disease

  • Correspondence
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Green C, Picot J, Loveman E, et al. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer’s disease. Pharmacoeconomics 2005; 23 (12): 1271–1282

    Article  PubMed  CAS  Google Scholar 

  2. Loveman E, Green C, Kirby J, et al. Technology assessment report commissioned by the ill A Programme on behalf of The National Institute for Clinical Excellence. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine, and memantine for Alzheimer’s disease. Southampton: Southampton Health Technology Assessments Centre, 2004 Aug 27 [online]. Available from URL: http://www.nice.org.uk/page.aspx?0=24591O [Accessed 2006 May 22]

    Google Scholar 

  3. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer’s disease. NICE technology appraisal in development [online]. Available from URL: http://www.nice.org.uk [Accessed 2006 May 22]

  4. Modelling Alzheimer’s disease progression over time. In: Loveman E, Green C, Kirby J, et al. Technology assessment report commissioned by the ill A Programme on behalf of The National Institute for Clinical Excellence. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine, and memantine for Alzheimer’s disease. Southampton: Southampton Health Technology Assessments Centre, 2004 Aug 27: 157 [online]. Available from URL: http://www.nice.org.uk/page.aspx?0=245910 [Accessed 2006 May 22]

  5. Geldmacher D, Provenzano G, McRae T, et al. Donepezil is associated with delayed nursing home placement in patients with Alzheimer’s disease. J Am Geriatr Soc 2003; 51 (7): 937–944

    Article  PubMed  Google Scholar 

  6. Heyman A, Peterson B, Fillenbaum G, et al. Predictors of time to institutionalization of patients with Alzheimer’s disease: the CERAD experience, part XVII. Neurology 1997 May; 48 (5): 1304–1309

    Article  PubMed  CAS  Google Scholar 

  7. Severson MA, Smith GE, Tangalos EG, et al. Patterns and predictors of institutionalization in community-based dementia patients. J Am Geriatr Soc 1994; 42 (2): 181–185

    PubMed  CAS  Google Scholar 

  8. Holmes C, Wilkinson D, Dean C, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004; 63: 214–219

    Article  PubMed  CAS  Google Scholar 

  9. Gauthier S, Feldman H, Hecker J, et al. Functional, cognitive and behavioural effects of donepezil in patients with moderate Alzheimer’s disease: Donepezil MSAD Study Investigators Group. Curr Med Res Opinion 2002; 18 (6): 347–354

    Article  CAS  Google Scholar 

  10. Mobs R, Doody RS, Morris JC, et al. 1-Year, placebo controlled preservation of function survival study of donepezil in AD patients. Neurology 2001; 57 (3): 481–488

    Article  Google Scholar 

  11. Lopez OL, Becker IT, Wisniewski S, et al. Cholinesterase inhibitor treatment alters the natural history of Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2002; 72: 3104

    Article  Google Scholar 

  12. Neumann P. Health utilities in Alzheimer’s disease and implications for cost-effectiveness analysis. Pharmacoeconomics. 2005; 23 (6): 537–541

    Article  PubMed  Google Scholar 

  13. Kavanagh S. Knapp M. Cognitive disability and direct care costs for elderly people. Br J Psychiatry 1999; 174: 53946

    Article  Google Scholar 

  14. Nelson T, Fernandez JL, Livingston G, et al. Does diagnosis determine delivery? The Islington study of older people’s needs and health care costs. Psychol Med 2004; 34: 147–155

    Article  PubMed  CAS  Google Scholar 

  15. Guidance on drugs for Alzheimer’s disease:HTA report [online]. Available from URL: http://www.nice.org.uk/page.aspx?o=14427 [Accessed 2006 May 22]

Download references

Acknowledgements

Professor Bosanquet has received payment for consulting services to Eisai Ltd.

Dr Andrew Yeates is an employee of Eisai Ltd.

Author information

Authors and Affiliations

  1. Imperial College, London, UK

    Nick Bosanquet (Professor of Health Policy)

  2. Eisai Europe Ltd, London, UK

    Andrew Yeates (Medical Adviser)

Authors
  1. Nick Bosanquet
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew Yeates
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bosanquet, N., Yeates, A. Modelling the Cost Effectiveness of Cholinesterase Inhibitors in the Management of Mild to Moderately Severe Alzheimer’s Disease. Pharmacoeconomics 24, 623–625 (2006). https://doi.org/10.2165/00019053-200624060-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200624060-00008

Keywords

Search

Navigation